JP2013523739A - Ｎ６−シクロペンチルアデノシン（ｃｐａ）、ｃｐａ誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法 - Google Patents

Ｎ６−シクロペンチルアデノシン（ｃｐａ）、ｃｐａ誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法 Download PDF

Info

Publication number
JP2013523739A
JP2013523739A JP2013502678A JP2013502678A JP2013523739A JP 2013523739 A JP2013523739 A JP 2013523739A JP 2013502678 A JP2013502678 A JP 2013502678A JP 2013502678 A JP2013502678 A JP 2013502678A JP 2013523739 A JP2013523739 A JP 2013523739A
Authority
JP
Japan
Prior art keywords
compound
formula
iop
hydroxy
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013502678A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523739A5 (enExample
Inventor
エヌ． キム、ノーマン
ケイ． マクビカー、ウィリアム
ジー． マコーレー、トーマス
ジャグタップ、プラカシュ
Original Assignee
イノテック ファーマシューティカルズ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イノテック ファーマシューティカルズ コーポレイション filed Critical イノテック ファーマシューティカルズ コーポレイション
Publication of JP2013523739A publication Critical patent/JP2013523739A/ja
Publication of JP2013523739A5 publication Critical patent/JP2013523739A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
JP2013502678A 2010-03-26 2011-03-25 Ｎ６−シクロペンチルアデノシン（ｃｐａ）、ｃｐａ誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法 Pending JP2013523739A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31810510P 2010-03-26 2010-03-26
US61/318,105 2010-03-26
PCT/US2011/030009 WO2011119969A1 (en) 2010-03-26 2011-03-25 Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016105169A Division JP2016147918A (ja) 2010-03-26 2016-05-26 Ｎ６−シクロペンチルアデノシン（ｃｐａ）、ｃｐａ誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法

Publications (2)

Publication Number Publication Date
JP2013523739A true JP2013523739A (ja) 2013-06-17
JP2013523739A5 JP2013523739A5 (enExample) 2014-05-08

Family

ID=44673656

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013502678A Pending JP2013523739A (ja) 2010-03-26 2011-03-25 Ｎ６−シクロペンチルアデノシン（ｃｐａ）、ｃｐａ誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法
JP2016105169A Pending JP2016147918A (ja) 2010-03-26 2016-05-26 Ｎ６−シクロペンチルアデノシン（ｃｐａ）、ｃｐａ誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016105169A Pending JP2016147918A (ja) 2010-03-26 2016-05-26 Ｎ６−シクロペンチルアデノシン（ｃｐａ）、ｃｐａ誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法

Country Status (16)

Country Link
US (4) US8476247B2 (enExample)
EP (1) EP2569325A4 (enExample)
JP (2) JP2013523739A (enExample)
KR (1) KR20130029050A (enExample)
CN (1) CN102933593A (enExample)
AU (1) AU2011230580A1 (enExample)
BR (1) BR112012023749A2 (enExample)
CA (1) CA2792266A1 (enExample)
CL (1) CL2012002613A1 (enExample)
CO (1) CO6630141A2 (enExample)
EA (1) EA201290958A1 (enExample)
MX (1) MX2012010724A (enExample)
PH (1) PH12012501906A1 (enExample)
SG (1) SG184221A1 (enExample)
WO (1) WO2011119969A1 (enExample)
ZA (1) ZA201207090B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011203897B2 (en) * 2010-01-11 2016-11-17 Inotek Pharmaceuticals Corporation Combination, kit and method of reducing intraocular pressure
BR112012023749A2 (pt) * 2010-03-26 2016-08-23 Inotek Pharmaceuticals Corp método para reduzir a pressão intraocular em humanos utilizando n6-ciclopentiladenosina (cpa), derivados de cpa ou pró-fármacos desses
BR112014018413A8 (pt) * 2012-01-26 2017-07-11 Inotek Pharmaceuticals Corp Polimorfos anidros de nitrato de metila [(2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-diidroxitetraidrofuran-2-il)] e processos de preparação do mesmo
EA201591433A1 (ru) 2013-03-15 2015-12-30 Инотек Фармасьютикалс Корпорейшн Офтальмологические составы
CA2967446A1 (en) * 2014-12-03 2016-06-09 Inotek Pharmaceuticals Corporation Methods of preventing, reducing or treating macular degeneration
CN119365476A (zh) * 2022-06-17 2025-01-24 上海森辉医药有限公司 一种环戊基腺苷衍生物及其药物用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
JP2009518295A (ja) * 2005-11-30 2009-05-07 イノテック ファーマシューティカルズ コーポレイション プリン化合物およびその使用方法

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4935635B1 (enExample) 1970-12-28 1974-09-25
CH563405A5 (enExample) 1971-09-10 1975-06-30 Duschinsky Robert Dr Schweiz I
DE2226295A1 (de) 1972-05-30 1973-12-20 Henning Berlin Gmbh Salpetersaeureester von purinnucleosiden und verfahren zur herstellung derselben
DE2342479A1 (de) 1973-08-23 1975-03-13 Merck Patent Gmbh Ribonucleosid-5'-nitrate und verfahren zu ihrer herstellung
GB2001976B (en) 1977-08-03 1982-03-10 Yamasa Shoyu Kk S-adenosyl-l-methionine compositions and production thereof
US4849311A (en) 1986-09-24 1989-07-18 Toa Nenryo Kogyo Kabushiki Kaisha Immobilized electrolyte membrane
US4968697A (en) 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US5219840A (en) 1987-04-06 1993-06-15 Sandoz Ltd. Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5591887A (en) 1987-04-30 1997-01-07 R-Tech Ueno, Ltd. Prostaglandins of the F series
ES2186670T3 (es) 1988-09-06 2003-05-16 Pharmacia Ab Derivados de prostaglandina para el tratamiento del glaucoma o la hipertension ocular.
US6187813B1 (en) 1990-04-10 2001-02-13 Pharmacia & Upjohn Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5140015A (en) 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US5280015A (en) 1990-09-05 1994-01-18 The United States Of America As Represented By The Department Of Health And Human Services 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides
JP3020580B2 (ja) 1990-09-28 2000-03-15 株式会社日立製作所 マイクロ波プラズマ処理装置
US5206222A (en) 1991-05-22 1993-04-27 Vanderbilt University Methods for the reduction of myocardial reperfusion injury
HU212570B (en) 1991-06-24 1996-08-29 Chinoin Gyogyszer Es Vegyeszet Process for producing 13,14-dihydro-15(r)-17-phenyl-18,19,20-trinor-pgf2alfa-isopropylester
US5407793A (en) 1991-10-18 1995-04-18 University Of Pittsburgh Of The Commonwealth System Of Higher Education An aqueous heart preservation and cardioplegia solution
US5278150A (en) 1992-04-24 1994-01-11 Whitby Research, Inc. 2-hydrazoadenosines and their utility for the treatmeat of vascular conditions
DK62692D0 (enExample) 1992-05-14 1992-05-14 Novo Nordisk As
AU4772493A (en) 1992-07-15 1994-02-14 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Sulfo-derivatives of adenosine
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5338430A (en) 1992-12-23 1994-08-16 Minnesota Mining And Manufacturing Company Nanostructured electrode membranes
US5443836A (en) 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
US5773423A (en) 1993-07-13 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
WO1995011681A1 (en) 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
US5620676A (en) 1994-03-08 1997-04-15 The United States Of America As Represented By The Department Of Health And Human Services Biologically active ATP analogs
EP0704215A3 (en) 1994-06-02 1998-04-01 Takeda Chemical Industries, Ltd. Inhibitor of vascular permeability enhancer
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
US5801159A (en) 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
CN1164122A (zh) 1996-03-01 1997-11-05 株式会社日立制作所 等离子处理机及其处理方法
WO1997033590A1 (en) 1996-03-13 1997-09-18 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
WO1997033879A1 (en) 1996-03-15 1997-09-18 Merck & Co., Inc. Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor
US5789416B1 (en) 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
CA2289731A1 (en) 1997-05-09 1998-11-12 The United States Of America, Represented By The Secretary, Department O F Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
US6358536B1 (en) 1997-10-15 2002-03-19 Thomas Jefferson University Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
US6329349B1 (en) 1997-10-23 2001-12-11 Trustees Of The University Of Pennsylvania Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid A and adenosine receptor agents
GB9723566D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723590D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
FR2775901B1 (fr) 1998-03-13 2000-07-21 Logeais Labor Jacques Sels de cetoacides et de derives amines, et leur utilisation pour la preparation de medicaments
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
AU765423B2 (en) 1998-07-16 2003-09-18 Government Of The United States Of America, The Methods for reducing intraocular pressure
WO2000023457A1 (en) 1998-10-16 2000-04-27 Pfizer Limited Adenine derivatives
IL127947A0 (en) 1999-01-07 1999-11-30 Can Fite Technologies Ltd Pharmaceutical use of adenosine agonists
US7214665B2 (en) 2001-10-01 2007-05-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6180615B1 (en) 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists
WO2000078776A2 (en) 1999-06-22 2000-12-28 Cv Therapeutics, Inc. Thiophene a2a receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
US6368573B1 (en) 1999-11-15 2002-04-09 King Pharmaceuticals Research And Development, Inc. Diagnostic uses of 2-substituted adenosine carboxamides
US6258793B1 (en) 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
GB9930071D0 (en) 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
US20010051612A1 (en) 2000-02-23 2001-12-13 Gloria Cristalli 2-Thioether A2A receptor agonists
US20030010454A1 (en) 2000-03-27 2003-01-16 Bailey Andrew D. Method and apparatus for varying a magnetic field to control a volume of a plasma
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
US6753322B2 (en) 2000-06-06 2004-06-22 Pfizer Inc 2-aminocarbonyl-9H-purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
CN1450896A (zh) 2000-07-28 2003-10-22 印斯拜尔药品股份有限公司 用吲哚衍生物降低眼内压的方法
US7589075B2 (en) 2001-01-16 2009-09-15 Can-Fite Biopharma Ltd. Use of an adenosine A3 receptor agonist for inhibition of viral replication
GB2372742A (en) 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
US20040204481A1 (en) 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
US20030013675A1 (en) 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
US6746635B2 (en) 2001-08-08 2004-06-08 Brown University Research Foundation Methods for micronization of hydrophobic drugs
CN101385738A (zh) 2002-04-18 2009-03-18 Cv医药有限公司 包括给予A1腺苷激动剂以及β受体阻滞剂、钙通道阻滞剂、或强心苷的治疗心律失常的方法
CA2482789A1 (en) 2002-04-30 2003-11-13 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treatglaucomatous retinopathies/optic neuropathies
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
CA2551169A1 (en) 2002-12-23 2004-07-08 Global Cardiac Solutions Pty Ltd Organ preconditioning, arrest, protection, preservation and recovery
GB2436255B (en) 2002-12-23 2007-11-28 Global Cardiac Solutions Pty L Organ preconditioning, arrest, protection, preservation and recovery
CA2468664C (en) 2003-06-03 2012-03-06 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
EP1718286A4 (en) 2004-01-22 2010-03-31 Nicox Sa NITROSIS AND / OR NITROSYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
CN101010085B (zh) 2004-05-26 2012-12-26 伊诺泰克制药公司 嘌呤衍生物作为腺苷a1受体激动剂及其用法
CN103087133B (zh) 2004-05-26 2016-09-14 伊诺泰克制药公司 嘌呤衍生物作为腺苷a1受体激动剂及其用法
US7271157B2 (en) 2004-07-12 2007-09-18 Cv Therapeutics, Inc. A1 adenosine receptor agonists
WO2007002139A2 (en) 2005-06-22 2007-01-04 The Trustees Of The University Of Pennsylvania Neuroprotection of retinal ganglion cells
EP2397148A3 (en) 2006-02-02 2012-04-25 Allergan, Inc. Compositions and methods for the treatment of ophthalmic disease
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
WO2007111954A2 (en) 2006-03-23 2007-10-04 Inotek Phamaceuticals Corporation Purine compounds and methods of use thereof
US8163737B2 (en) 2006-06-13 2012-04-24 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
AR062046A1 (es) 2006-07-25 2008-08-10 Osmotica Pharmaceutical Argentina S A Soluciones oftalmicas
AU2007307157A1 (en) * 2006-10-06 2008-04-17 The Trustees Of The University Of Pennsylvania Effective delivery of cross-species A3 adenosine-receptor antagonists to reduce intraocular pressure
AU2007316641B2 (en) 2006-11-10 2013-01-10 Basf Se Crystalline modification of fipronil
EP2099468B1 (en) 2006-12-05 2018-07-11 The Royal Institution for the Advancement of Learning/McGill University Methods of use of trk receptor modulators
JP2008266143A (ja) 2007-04-16 2008-11-06 Santen Pharmaceut Co Ltd アデノシン誘導体を有効成分として含有する緑内障治療剤
WO2009048605A1 (en) 2007-10-11 2009-04-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists
US20100272711A1 (en) 2007-12-12 2010-10-28 Thomas Jefferson University Compositions and methods for the treatment and prevention of cardiovascular diseases
CA2714516A1 (en) 2008-02-07 2009-08-13 Gilead Palo Alto, Inc. Abca-1 elevating compounds and the use thereof
ES2766257T3 (es) 2008-11-13 2020-06-12 Massachusetts Gen Hospital Métodos y composiciones para regular la homeostasis del hierro mediante la modulación de bmp-6
HRP20151200T1 (hr) 2009-05-01 2016-01-15 Inotek Pharmaceuticals Corporation Metoda za snižavanje intraokularnog tlaka kod ljudi
MX2012004225A (es) * 2009-10-26 2012-06-08 Inotek Pharmaceuticals Corp Formulacion oftalmica y metodo de fabricacion de la misma.
WO2011077435A1 (en) 2009-12-22 2011-06-30 Bar-Ilan University Compositions and methods for reducing intraocular pressure
AU2011203897B2 (en) 2010-01-11 2016-11-17 Inotek Pharmaceuticals Corporation Combination, kit and method of reducing intraocular pressure
US20110217262A1 (en) 2010-03-05 2011-09-08 Kornfield Julia A Treatment of Ocular Surface Disorders by Increasing Conjunctival Vascular Permeability
ME02594B (me) 2010-03-19 2017-06-20 Inotek Pharmaceuticals Corp Kombinovane kompozicje adenozinskih a1 agonista i ne-selektivnih beta- adrenergičnih receptor blokera za snižavanje intraokularnog pritiska
ES2613254T3 (es) * 2010-03-19 2017-05-23 Inotek Pharmaceuticals Corporation Composiciones de combinación de agonistas de adenosina A1 e inhibidores de anhidrasa carbónica para reducir la presión intraocular
WO2011119919A1 (en) 2010-03-26 2011-09-29 Inotek Pharmaceuticals Corporation Adenosine compounds and their use thereof
BR112012023749A2 (pt) 2010-03-26 2016-08-23 Inotek Pharmaceuticals Corp método para reduzir a pressão intraocular em humanos utilizando n6-ciclopentiladenosina (cpa), derivados de cpa ou pró-fármacos desses
US20140241990A1 (en) 2011-09-30 2014-08-28 Tufts University Methods of using adenosine a1 receptor activation for treating depression
BR112014018413A8 (pt) 2012-01-26 2017-07-11 Inotek Pharmaceuticals Corp Polimorfos anidros de nitrato de metila [(2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-diidroxitetraidrofuran-2-il)] e processos de preparação do mesmo
US20140275128A1 (en) 2013-03-15 2014-09-18 Inotek Pharmaceuticals Corporation Method of providing ocular neuroprotection
EA201591433A1 (ru) * 2013-03-15 2015-12-30 Инотек Фармасьютикалс Корпорейшн Офтальмологические составы

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
JP2009518295A (ja) * 2005-11-30 2009-05-07 イノテック ファーマシューティカルズ コーポレイション プリン化合物およびその使用方法

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
JPN6014025124; Ｃｕｒｒ．　Ｅｙｅ　Ｒｅｓ． Ｖｏｌ．１１　Ｎｏ．５, 1992, ｐｐ．４５３-４５８ *
JPN6014025128; Ｊ．　Ｐｈａｒｍａｃｏｌ．　Ｅｘｐ．　Ｔｈｅｒ． Ｖｏｌ．２７３　Ｎｏ．１, 1995, ｐｐ．３２０-３２６ *
JPN6014025132; Ｅｘｐ．　Ｅｙｅ　Ｒｅｓ． Ｖｏｌ．６４, 1997, ｐｐ．９７９-９８９ *
JPN6015008807; Ｂｉｏｍａｔｅｒｉａｌｓ Ｖｏｌ．２６, 2005, ｐｐ．１２９９-１３０６ *
JPN6015008808; Ｐｈａｒｍ．　Ｒｅｓ． Ｖｏｌ．１８　Ｎｏ．４, 2001, ｐｐ．５３１-５３５ *
JPN6015008810; Ｊ．　Ｐｈａｒｍ．　Ｓｃｉ． Ｖｏｌ．８３　Ｎｏ．１, 1994, ｐｐ．４６-５３ *
JPN6015008812; Ｉｎｔ．　Ｊ．　Ｐｈａｒｍ． Ｖｏｌ．３０７, 2006, ｐｐ．１０３-１１３ *
JPN6015008813; Ｊ．　Ｏｃｕｌ．　Ｐｈａｒｍａｃｏｌ． Ｖｏｌ．１０　Ｎｏ．１, 1994, ｐｐ．３７９-３８３ *
JPN6015008815; Ａｃｔａ　Ｔｅｃｈｎｏｌｏｇｉａｅ　ｅｔ　Ｌｅｇｉｓ　Ｍｅｄｉｃａｍｅｎｔｉ Ｖｏｌ．１３, 2002, ｐｐ．４９-５７ *

Also Published As

Publication number Publication date
SG184221A1 (en) 2012-10-30
US20110245195A1 (en) 2011-10-06
KR20130029050A (ko) 2013-03-21
US9289383B2 (en) 2016-03-22
AU2011230580A1 (en) 2012-10-11
US20150080330A1 (en) 2015-03-19
MX2012010724A (es) 2012-11-12
CA2792266A1 (en) 2011-09-29
CO6630141A2 (es) 2013-03-01
ZA201207090B (en) 2014-03-26
US8476247B2 (en) 2013-07-02
CN102933593A (zh) 2013-02-13
JP2016147918A (ja) 2016-08-18
US20140018314A1 (en) 2014-01-16
US8895530B2 (en) 2014-11-25
EP2569325A4 (en) 2013-10-09
EA201290958A1 (ru) 2013-04-30
BR112012023749A2 (pt) 2016-08-23
CL2012002613A1 (es) 2012-12-21
US20160158268A1 (en) 2016-06-09
EP2569325A1 (en) 2013-03-20
WO2011119969A1 (en) 2011-09-29
PH12012501906A1 (en) 2013-01-14

Similar Documents

Publication Publication Date Title
AU2010242943B2 (en) Method of reducing intraocular pressure in humans
JP2016147918A (ja) Ｎ６−シクロペンチルアデノシン（ｃｐａ）、ｃｐａ誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法
US8501708B2 (en) Adenosine compounds and their use thereof
EP2523669B1 (en) Combination, kit and method of reducing intraocular pressure
EP2968388A1 (en) A method of providing ocular neuroprotection
HK1167599B (en) Method of reducing intraocular pressure in humans

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150810

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160126